GUERBET : Watch Guerbet experience at ECR 2015 in Vienna
Le 19 mars 2015 à 15:10
Partager
Watch Guerbet experience at ECR 2015 in Vienna
19.03.2015 14:46
The ECR, European Congress of Radiology, came to an end on Sunday 8 March. This year, we presented our solutions in our 4 growing business segments: MRI, X-ray, Interventional radiology and Medical devices.
These 4 days have been rich in meetings, networking and talks about projects with radiologists and societies on the Guerbet booth. We presented 13 scientific communications and an interesting symposium moderated by Professor Lauenstein (Germany) focusing on guidelines and practices for MRI, X-ray and Interventional radiology. More than 200 professionals attended the presentations by Professors Radbruch (Germany), Caramella (Italy) and Lauenstein (Germany).
In MRI , Guerbet presented its leading solution in Europe that covers all kind of patients and many indications with a worldwide experience.
InX-ray , Guerbet focuses on optimizing patient safety and diagnostic efficacy with adapted iodine dose. The Group also displayed a global solution including an innovative packaging which is environmental friendly and improves patient workflow.
In Interventional radiology (IR), Guerbet displayed its main contrast agent for oncology and emphasized involvement in R&D for IR solutions.
In Medical Devices , Guerbet expands with FlowSens®, a very innovative dual soft bag injector for CT medical imaging, coming with its wide range of dedicated disposables. New features were launched this year!
Guerbet figure parmi les leaders européens de la fabrication et de la commercialisation de produits de contraste destinés à l'imagerie médicale. Les produits du groupe permettent de visualiser les différents organes, les systèmes lymphatiques et vasculaires du corps humain en les rendant opaques. Le CA par famille de produits se répartit comme suit :
- produits pour imagerie par rayons X (55,4%) ;
- produits pour IRM (32,7%) ;
- autres (11,9%) : produits de contraste destinés notamment aux échographies et à la médecine nucléaire, et produits de chimie fine.
A fin 2023, le groupe dispose de 8 sites de production implantés en France (4), aux Etats-Unis (2), en Irlande et au Brésil.
39,7% du CA est réalisé en Europe.
GUERBET 
